Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds

Journal of Clinical Microbiology

Volumn 50, Issue 6, 2012, Pages 1927-1935

  Tropé, Ameli ^a   Sjøborg, Katrine D ^b   Nygård, Mari ^c   Røysland, Kjetil ^c   Campbell, Suzanne ^c   Alfsen, G Cecilie ^a   Jonassen, Christine M ^a  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b Oestfold Hospital Trust   (Norway)

^c Cancer Registry of Norway ^*  (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN E6; PROTEIN E7; VIRUS DNA; VIRUS RNA;

ADULT; AGED; ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE CYTOLOGY; CANCER GRADING; CANCER INCIDENCE; CANCER SCREENING; DIAGNOSTIC KIT; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HUMAN; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION CYTOLOGY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPEAT PROCEDURE; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYTOLOGICAL TECHNIQUES; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; NORWAY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROSPECTIVE STUDIES; RNA, VIRAL; SWITZERLAND; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS;

EID: 84862087483     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00265-12     Document Type: Article

References (40)

1. Arbyn M, et al. 2009. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J. Cell Mol. Med. 13:648-659.
2. Arbyn M, Roelens J, Martin-Hirsch P, Leeson S, Wentzensen N. 2011. Use of HC2 to triage women with borderline and mild dyskaryosis in the UK. British J. Cancer 105:877-880.
3. Arbyn M, et al. 2006. Chapter 9. Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(Suppl 3):89.
4. Bais AG, et al. 2005. Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. Int. J. Cancer 116:122-129. (Pubitemid 40827765)
5. Benevolo M, et al. 2011. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J. Clin. Microbiol. 49:2643-2650.
6. Berkhof J, et al. 2006. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int. J. Cancer 118:1759-1768. (Pubitemid 43376440)
7. Bulkmans NW, et al. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370: 1764-1772.
8. Burger EA, Kornor H, Klemp M, Lauvrak V, Kristiansen IS. 2011. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol. Oncol. 120:430-438.
9. Cancer Registry of Norway. 2012. Kvalitetsmanual. Masseundersø kelsen mot livmorhalskreft (Quality assurance manual. Cervical Cancer Screening Programme.) Cancer Registry of Norway. http://www.kreftregisteret.no/Global/ Masseundersøkelsen%20mot%20livmorhalskreft/Kvalitetsmanual/ Kvalitetsmanual-2012-oppslag.pdf.
10. Castle PE, Gage JC, Wheeler CM, Schiffman M. 2011. The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy. Obstet. Gynecol. 118:1222-1229.
11. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. 2007. Risk assessment to guide the prevention of cervical cancer. Am. J. Obstet. Gynecol. 197:356.e1-356.e6. doi:org/10.1016/j.ajog.2007.07.049.
12. Dillner L, et al. 2011. Randomized health services study of human papillomavirus- based management of low-grade cytological abnormalities. Int. J. Cancer 129:151-159.
13. Guido R, Schiffman M, Solomon D, Burke L. 2003. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am. J. Obstet. Gynecol. 188:1401-1405. (Pubitemid 36741265)
14. Haldorsen, T, Dahle B. 2012, posting date. Secondary screening with HPV in the cervical cancer screening program in Norway. The Cancer Registry of Norway. http://www.kreftregisteret.no/en/General/News/HPV-test-Effective-in-the- prevention-of-cervical-cancer/.
15. Jordan J, et al. 2008. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology 19:342-354.
16. Kelly RS, Patnick J, Kitchener HC, Moss SM. 2011. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br. J. Cancer 105:983-988.
17. Larsen IK, et al. 2009. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur. J. Cancer 45:1218 -1231.
18. Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ. 2009. Validation of high-risk HPV tests for primary cervical screening. J. Clin. Virol. 46(Suppl 3):S1-S4.
19. Meijer CJ, et al. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124:516-520.
20. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. 1998. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet. Gynecol. 92:727-735. (Pubitemid 28440819)
21. Molden T, et al. 2005. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int. J. Cancer 114:973-976.
22. Naucler P, et al. 2009. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J. Natl. Cancer Inst. 101:88-99.
23. Norwegian Gynaecological Association. April 2009, posting date. Veileder i gynekologisk onkologi. (Norwegian gynecological oncology guidelines.) http://legeforeningen.no/Fagmed/Norsk-gynekologisk-forening/Veiledere/ veileder-i-gynekologisk-onkologi-2009/premaligne-lidelser-i-cervix/.
24. Nygard JF, Nygard M, Skare GB, Thoresen SO. 2006. Pap smear screening in women under 30 in the Norwegian Coordinated Cervical Cancer Screening Program, with a comparison of immediate biopsy vs Pap smear triage of moderate dysplasia. Acta Cytol. 50:295-302. (Pubitemid 43841438)
25. Ovestad IT, et al. 2011. Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol. Oncol. 123:278-283.
26. Ratnam S, et al. 2011. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 assay but more specific at detecting cervical precancer and cancer. J. Clin. Microbiol. 49:557-564.
27. Rijkaart DC, et al. 2012. Evaluation of 14 triage strategies for HPV DNApositive women in population-based cervical screening. Int. J. Cancer 130: 602-610.
28. Schiffman M, et al. 2011. Human papillomavirus testing in the prevention of cervical cancer. J. Natl. Cancer Inst. 103:368-383.
29. Scott DR, et al. 2002. Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer 96:14-20. (Pubitemid 34194315)
30. Sellors JW, Sankaranarayanan R. 2003. Colposcopy and treatment of cervical intraepithelial neoplasia: a beginners' manual. Chapter 2. An introduction to cervical intraepithelial neoplasia (CIN). IARC Screening Group. http://screening.iarc.fr/colpochap.php?lang=1&chap=2.
31. Solomon D, et al. 2002. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287:2114-2119. (Pubitemid 34437346)
32. Sorbye SW, Fismen S, Gutteberg T, Mortensen ES. 2010. Triage of women with minor cervical lesions: data suggesting a "test and treat"approach forHPVE6/E7mRNAtesting. PLoS One 5:e12724. doi:10.1371/journal.pone.0012724.
33. Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES. 2010. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J. Virol. Methods 169:219-222.
34. Szarewski A, et al. 2008. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev. 17:3033-3042.
35. Szarewski A, et al. 14 March 2012. A comparison of seven tests for high grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J. Clin. Microbiol. [Epub ahead of print.] doi:10.1128/JCM.00181-12.
36. Trope A, et al. 2011. Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia. Gynecol. Oncol. 123:257-262.
37. Trope A, et al. 2009. Performance of human papillomavirus DNA and mRNAtesting strategies for women with and without cervical neoplasia. J. Clin. Microbiol. 47:2458-2464.
38. Wahlstrom C, Iftner T, Dillner J, Dillner L. 2007. Population-based study of screening test performance indices of three human papillomavirus DNA tests. J. Med. Virol. 79:1169-1175. (Pubitemid 47015417)
39. Wentzensen N, Gravitt PE, Solomon D, Wheeler CM, Castle PE. 2009. A study of Amplicor human papillomavirusDNAdetection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study. Cancer Epidemiol. Biomarkers Prev. 18: 1341-1349.
40. zur Hausen H. 1994. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr. Top. Microbiol. Immunol. 186:131-156.